{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T03:26:59Z","timestamp":1787110019608,"version":"build-2736575974"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":3062,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anales de Pediatr\u00eda"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.anpedi.2017.03.007","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T13:01:52Z","timestamp":1498654912000},"page":"209-215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diez a\u00f1os de experiencia con el primer biosimilar autorizado de hormona del crecimiento recombinante humana en la pr\u00e1ctica cl\u00ednica habitual"],"prefix":"10.1016","volume":"88","author":[{"given":"Juan Pedro","family":"L\u00f3pez-Siguero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Palla Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mart\u00ednez Busto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Jos\u00e9","family":"Rebollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Pombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anpedi.2017.03.007_bib0085","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s13554-013-0011-z","article-title":"Switching from originator to biosimilar human growth hormone using dialogue teamwork: Single-center experience from Sweden","volume":"3","author":"Flodmark","year":"2013","journal-title":"Biol Ther."},{"key":"10.1016\/j.anpedi.2017.03.007_bib0090","unstructured":"EMA. Preguntas y respuestas sobre medicamentos biosimilares (medicamentos biol\u00f3gicos similares). 2012 [consultado Ago 2016]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/Medicine_QA\/2009\/12\/WC500020062.pdf"},{"key":"10.1016\/j.anpedi.2017.03.007_bib0095","unstructured":"Kirchlechner T. Nueva generaci\u00f3n de productos biol\u00f3gicos en Europa: biosimilares [monograf\u00eda en Internet]. Zaragoza: Sandoz; 2003 [consultado Oct 2016]. Disponible en: http:\/\/www.sefh.es\/54congresoInfo\/documentos\/ponencias\/1108.pdf"},{"key":"10.1016\/j.anpedi.2017.03.007_bib0100","first-page":"359","article-title":"Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope\u00ae in the treatment of growth hormone deficient children: Results of a phase III study","volume":"72","author":"Romer","year":"2009","journal-title":"Horm Res."},{"key":"10.1016\/j.anpedi.2017.03.007_bib0105","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s12325-015-0181-9","article-title":"A follow-up study to monitor adult height among Spanish children with growth hormone deficiency who received biosimilar human recombinant growth hormone Omnitrope\u00ae during a phase III clinical trial","volume":"32","author":"Borr\u00e1s P\u00e9rez","year":"2015","journal-title":"Adv Ther."},{"key":"10.1016\/j.anpedi.2017.03.007_bib0110","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s12325-011-0063-8","article-title":"Long-term safety and efficacy of the recombinant human growth hormone Omnitrope\u00ae in the treatment of Spanish growth hormone deficient children: Results of a phase III study","volume":"28","author":"L\u00f3pez-Siguero","year":"2011","journal-title":"Adv Ther."},{"key":"10.1016\/j.anpedi.2017.03.007_bib0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2042018813479644","article-title":"Design of, and first data from, PATRO Children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope\u00ae in children requiring growth hormone treatment","volume":"4","author":"Pfaffle","year":"2013","journal-title":"Ther Adv Endocrinol Metab."},{"key":"10.1016\/j.anpedi.2017.03.007_bib0120","unstructured":"Sandoz Farmac\u00e9utica, SA. Ficha t\u00e9cnica o resumen de las caracter\u00edsticas del producto Omnitrope\u00ae (somatropina) [consultado Sep 2016]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/000607\/WC500043695.pdf"},{"key":"10.1016\/j.anpedi.2017.03.007_bib0125","first-page":"24","article-title":"Perfil de seguridad en el metabolismo hidrocarbonado, lip\u00eddico y tiroideo en ni\u00f1os tratados con hormona de crecimiento biosimilar","author":"Rivero Mart\u00edn","year":"2014","journal-title":"BioPharmaceuticals."},{"key":"10.1016\/j.anpedi.2017.03.007_bib0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.anpedi.2010.10.005","article-title":"Estudios espa\u00f1oles de crecimiento: situaci\u00f3n actual, utilidad y recomendaciones de uso","volume":"74","author":"S\u00e1nchez Gonz\u00e1lez","year":"2011","journal-title":"An Pediatr (Barc)."},{"key":"10.1016\/j.anpedi.2017.03.007_bib0135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s13554-014-0017-1","article-title":"Switching to Omnitrope\u00ae from other recombinant human growth hormone therapies: A retrospective study in an integrated healthcare system","volume":"4","author":"Rashid","year":"2014","journal-title":"Biol Ther."},{"key":"10.1016\/j.anpedi.2017.03.007_bib0140","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.reuma.2015.03.009","article-title":"Position paper from the Spanish Society of Rheumatology on biosimilar drugs","volume":"11","author":"Abad Hern\u00e1ndez","year":"2015","journal-title":"Reumatol Clin."},{"issue":"Supl. 1","key":"10.1016\/j.anpedi.2017.03.007_bib0145","first-page":"127","article-title":"Evaluaci\u00f3n intermedia del estudio PATRO Ni\u00f1os \u2014 Estudio longitudinal en pacientes espa\u00f1oles tratados con hormona de crecimiento humana recombinante biosimilar. 36 Congreso de la Sociedad Espa\u00f1ola de Endocrinolog\u00eda Pedi\u00e1trica, Sevilla","volume":"5","author":"Lechuga","year":"2014","journal-title":"Rev Esp Endocrinol Pediatr."},{"key":"10.1016\/j.anpedi.2017.03.007_bib0150","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/2042018812444152","article-title":"Rationale and design of PATRO Adults, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope\u00ae for the treatment of adult patients with growth hormone deficiency","volume":"3","author":"Beck-Peccoz","year":"2012","journal-title":"Ther Adv Endocrinol Metab."},{"key":"10.1016\/j.anpedi.2017.03.007_bib0155","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1210\/jc.2009-1326","article-title":"Prevalence of metabolic syndrome in adult hypopituitary growth hormone (1)-deficient patients before and after GH replacement","volume":"95","author":"Attanasio","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.anpedi.2017.03.007_bib0160","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1530\/EJE-11-0599","article-title":"Prevalence and characteristics of the metabolic syndrome in 2479 hypopituitary patients with adult-onset GH deficiency before GH replacement: A KIMS analysis","volume":"165","author":"Verhelst","year":"2011","journal-title":"Eur J Endocrinol."}],"container-title":["Anales de Pediatr\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1695403317301522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1695403317301522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:45:53Z","timestamp":1787107553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1695403317301522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1695403317301522"],"URL":"https:\/\/doi.org\/10.1016\/j.anpedi.2017.03.007","relation":{},"ISSN":["1695-4033"],"issn-type":[{"value":"1695-4033","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diez a\u00f1os de experiencia con el primer biosimilar autorizado de hormona del crecimiento recombinante humana en la pr\u00e1ctica cl\u00ednica habitual","name":"articletitle","label":"Article Title"},{"value":"Anales de Pediatr\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anpedi.2017.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}